Mutation characterization and heterodimer analysis of patients with leukocyte adhesion deficiency: Including one novel mutation by Teimourian, S. et al.
Contents lists available at ScienceDirect
Immunology Letters
journal homepage: www.elsevier.com/locate/immlet
Mutation characterization and heterodimer analysis of patients with
leukocyte adhesion deﬁciency: Including one novel mutation
Shahram Teimouriana,b,⁎, Martin De Boerc, Dirk Roosc, Anna Isaiand, Ehsan Moghanloob,e,
Sharhzad Lashkarya, Bita Hassania, Hasan Mollanooria, Vahid Babaeia, Asaad Azarnezhadf,g
a Department of Medical Genetics, Iran University of Medical Sciences IUMS, Tehran, Iran
b Pediatric Infectious Diseases Research Center, Department of Infectious Diseases, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
c Sanquin Research, and Karl Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
d Department of Pathology, Tehran University of Medical Sciences (TUMS). Tehran, Iran
e Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
f Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
g Cellular and Molecular Research Center, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Kurdistan, Iran
A R T I C L E I N F O
Keywords:
Leukocyte adhesion deﬁciency type I
Immunodeﬁciency
Mutation
Genetic testing
CD18
A B S T R A C T
Background and aim: Leukocyte adhesion deﬁciency type 1 (LAD-I) is a rare, autosomal recessive disorder of
neutrophil migration, characterized by severe, recurrent bacterial infections, inadequate pus formation and
impaired wound healing. The ITGB2 gene encodes the β2 integrin subunit (CD18) of the leukocyte adhesion cell
molecules, and mutations in this gene cause LAD-I. The aim of the current study was to investigate the mutations
in patients diagnosed with LAD-I and functional studies of the impact of two previously reported and a novel
mutation on the expression of the CD18/CD11a heterodimer.
Materials and methods: Blood samples were taken from three patients who had signed the consent form. Genomic
DNA was extracted and ITGB2 exons and ﬂanking intronic regions were ampliﬁed by polymerase chain reaction.
Mutation screening was performed after Sanger sequencing of PCR products. For functional studies, COS-7 cells
were co-transfected with an expression vector containing cDNA encoding mutant CD18 proteins and normal
CD11a. Flow cytometry analysis of CD18/CD11a expression was assessed by dimer-speciﬁc IB4 monoclonal
antibody.
Results: Two previously reported mutations and one novel mutation,p. Cys562Tyr, were found. All mutations
reduced CD18/CD11 heterodimer expression.
Conclusion: Our strategy recognized the p.Cys562Tyr mutation as a pathogenic alteration that does not support
CD18 heterodimer formation. Therefore, it can be put into a panel of carrier and prenatal diagnosis programs.
1. Introduction
Integrins are transmembrane receptors that are involved in cell–cell
and cell-extracellular matrix. Interactions, immunity, wound healing,
hemostasis and the development throughout the body. These proteins
are large, heterodimeric cell adhesion molecules composed of α and β
subunits. The β2 integrins (CD18) are β subunits in a family of
heteromeric proteins: αLβ2 (LFA-1, CD11a/CD18), αMβ2 (Mac-1 or
CR3, CD11b/CD18), αXβ2 (p150,95, CD11c/CD18) and αDβ2 (CR4,
CD11d/CD18). These four proteins are expressed on leukocytes, except
for αDβ2 (CR4, CD11d/CD18), which is only expressed on macro-
phages. The integrin β2 family has a crucial role in the immune system,
because they recruit and activate leukocytes during inﬂammation
[1–6]. Integrins can bind to extracellular matrix (ECM) glycoproteins,
including collagens, ﬁbronectins, laminins, and cellular receptors such
as vascular cell adhesion molecule-1 (VCAM-1) and the intercellular
cell adhesion molecule (ICAM) family [7] .Genetic alterations in the
beta2-integrin gene play an important role in the pathophysiology of
several diseases and genetic syndromes, including Leukocyte Adhesion
Deﬁciency (LAD-I) and Systemic Lupus Erythematosus (SLE) [3]
CD18 is encoded by a gene located on chromosome 21q22.3 known
as ITGB2. CD18 deﬁciency leads to incomplete formation and/or
dysfunction of β2 integrins. More than 100 mutations have been
reported in the ITGB2 gene, including missense mutations (40%), splice
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Fig. 1. Electropherogram of mutations.a) c.382 C>A on (−) strand leading to; p. Asp128Tyr b) c.754 T>C on (+) strand leading to; p.Trp282 Arg, and ﬁnally c) c.1885 G>A on (+)
strand leading to; p. Cys563Tyr.Normal sequence is shown above each panel.
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site mutations (14%), small deletions (15%), large deletions (11%) and
other mutations (10%) [1,8]. These mutations are mostly located in a
conserved domain of CD18 known as Von Willebrand Factor type A
(VWFA) [1,9]. Most missense mutations interfere with integrin hetero-
dimer expression, whereas other missense mutations allow normal
expression of integrin heterodimers but without adhesive capacity.
Some mutations support subnormal expression of integrin heterodimers
with adhesion activity, while a few do not aﬀect the expression of
integrins [2].
Inﬂammation due to infection or tissue injury induces a cascade of
cellular and microvascular reactions that allow the removal of patho-
gens or cell debris, and ﬁnally give rise to wound healing, repair and
homeostasis [10,11]. The process of inﬂammation includes recruitment
(migration) of immune cells such as polymorphonuclear neutrophils
(PMN) and monocytes/macrophages to the site of infection. Essential
steps during leukocyte recruitment include tethering and rolling over
the vasculature, activation, ﬁrm adhesion, intraluminal crawling, and
extravasation. Firm adhesion and crawling are largely mediated by β2
integrins [12,13]. Therefore, the clinical picture of LAD-I is character-
ized by marked leukocytosis, neutrophilia and localized bacterial
infections that are diﬃcult to detect until they have progressed to an
extensive level secondary to the lack of leukocyte recruitment at the site
of infection [14]. The level of expression of β2 integrins has a direct
relationship with two relatively distinct clinical phenotypes: Expression
of less than 1% of normal CD18/CD11 is seen in the severe form of LAD-
I, whereas 3–10% of expression is related with a moderate phenotype
[15]. Leukocyte adhesion deﬁciency (LAD) is a type of autosomal
recessive immunodeﬁciency disorder which is divided into three
subgroups, including LAD-I, LAD-II and LAD-III [16]. LAD-I is a rare
disease (1 in every 100,000 live births) [17]. As migration capacity of
neutrophils is eliminated in LAD-I, these patients consequently suﬀer
from serious bacterial and fungal infection since their neonatal period
[18]. Delayed separation of the umbilical cord (after 19 ± 1 day),
omphalitis, sepsis, impaired wound healing and impaired pus forma-
tion, periodontitis, otitis media, cellulitis, pneumonia,colitis, sepsis,
ophtus,cervical lymphadenopathy, osteomyelitis are other classical
clinical characteristics of LAD-I patients [1].
To answer the question how genetic mutations exactly aﬀect the
expression of the encoded protein we investigated the genetic muta-
tions in three patients with LAD-I by PCR sequencing, and then
analyzed the eﬀect of the mutations on expression and heterodimer
formation of CD18 and the CD11a subunit in vitro.
2. Materials and methods
2.1. Patients
In the current study, three patients diagnosed with LAD-I were
referred to a children’s medical center in Iran in 2016. These patients
were from consanguineous marriage. No positive family history was
detected in their pedigrees. The disease was conﬁrmed according toTa
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Table 2
In silico prediction of p.Asp128Tyr, p.Trp252Arg, and the novel mutation of p.Cys562Tyr
on CD18 structure and stability. These residues are conserved in: Mus musculus (Mouse),
sus scrofa (Pig), Bos Taurus (Cow), Rattus norvegicus (Rat), and equine (horse).
Bioinformatics
prediction tools
p.Asp128Tyr p.Trp252Arg p.Cys562Tyr novel
SIFT DAMAGING DAMAGING DAMAGING
PolyPhen-2 Probably
damaging
Probably
damaging
Probably
damaging
MUpro DECREASE of
stability of protein
structure
DECREASE of
stability of
protein structure
DECREASE of
stability of protein
structure
Project HOPE Disturbed Disturbed Disturbed
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Fig. 2. Expression of LAF-1 on CD11a/CD18 transfected COS-7 cells. Subtracted proﬁles; those obtained with transfectants of CD11a/CD18 minus proﬁles of the transfectants with CD18
alone are shown, obtained with CellQuest software, A: Cotransfection of wild-type CD18 with wild-type CD11a, B: Cotransfection of CD18Asp128Tyr with wild-type CD11a, C: co-
transfection of CD18Trp252Arg with wild-type CD11a, and D: co-transfection of CD18Cys562Tyr with wild-type CD11a.
S. Teimourian et al. Immunology Letters 187 (2017) 7–13
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clinical diagnosis and laboratory ﬁndings. This included recurrent
severe infections, impaired pus formation, impaired wound healing,
delay in umbilical cord separation and omphalitis as clinical features,
and ﬂow cytometery study of CD18 and/or CD11b expression as
laboratory data. Consent forms were signed by the parents of all
patients to guarantee that they understood and participated voluntarily.
The ethical committee of the Iran University of Medical Sciences
(Tehran) approved the current study.
2.2. cDNA ampliﬁcation and sequencing
RNA extraction from mononuclear leukocytes and cDNA synthesis
were performed according to the manufacturer's instructions (High
Pure RNA Isolation Kit, Roche). As reported before [15], the coding
region of CD18 cDNA was ampliﬁed by polymerase chain reaction
(PCR). The PCR products were run on agarose gels to ensure the size of
ampliﬁed targets. Finally, PCR ampliﬁed products were sequenced by
Sanger sequencing in both directions.
2.3. Sequencing of genomic DNA
Blood samples were taken from all participants, and DNA was
extracted by salting-out [19]. Altogether, sixteen coding exons and
their ﬂanking intronic sequences were PCR ampliﬁed in the ABI 9700
thermal cycler. The PCR reaction took place in a volume of 25 μl,
including 12.5 μl of Taq DNA Pol. 2X Master mix Red (Ampliqon,
Denmark), 1 μl of each primer (15 pmol/μl), 1.5 μl of genomic DNA
(100 ng/μl) and 9 μl of distilled water. DNA was ampliﬁed according to
the following program: initial denaturation at 95 °C for 4 min, and 30
cycles of denaturation at 95 °C for 32 s, primer annealing at 52–62 °C
for 30 s and DNA ampliﬁcation at 72 °C for 32–80 s. These steps were
followed by a ﬁnal DNA ampliﬁcation at 72 °C for 4 min. The accuracy
of the target ampliﬁcation was analyzed by electrophoresis of PCR
products on 2% agarose gel. Primer sequences of target regions have
been mentioned previously [15].
PCR products were cleaned up with PCR puriﬁcation kit (High Pure
PCR Product Puriﬁcation Kit − Roche Life Science). The puriﬁed
samples together with 10 μl of related primers used to obtain these PCR
products were used for sequencing. Sequencing of samples was
performed in an ABI 3130 XL DNA Analyzer (Applied Biosystems,
Foster City, CA, USA). Sequencing results were analyzed by Chromas
software version 2.33. Alterations were found by alignment of sequen-
cing results against a reference sequence database. Numbering of DNA
and protein sequence was performed based on GenBank entry NM_
000211.4 and NP_000202.3 as reference. Pathological impact of found
variants was predicted by tools consisting of PolyPhen-2 and SIFT.
2.4. Functional heterodimer formation study
2.4.1. Mutation insertion in cDNA and construction of expression plasmid
cDNA encoding the three mutant CD18 or normal CD18 proteins
together with the CD11a subunit were cloned in the expression vector
of pvitro 2 neo. The ability of the three CD18 mutant proteins to form a
stable heterodimer with CD11a was investigated with ﬂow cytometery.
The introduction of mutations in the putative pvitro 2 neo was
performed with the QuikChange II XL site-directed mutagenesis kit
(Stratagene) with the wild-type vector as a template. Brieﬂy, mutant
strand synthesis was performed by initial denaturation at 95 °C for
1 min, followed by 18 thermal cycles at 95 °C for 50 s, 60 °C for 50 s,
and 68 °C for 9 min 24 s, with a ﬁnal extension at 68 °C for 7 min. The
construct was sequenced to check that only the desired mutations had
been introduced. The expression vector has two cloning sites: one for
cloning of nucleic acids encoding mutant CD18 and another for cloning
of normal CD11a subunit.
2.5. Cell culture and transfection
COS-7 cells were purchased from the Pasteur Institute of Iran. Cells
were cultured in DMEM (Invitrogen) supplemented with 10% (v/v)
fetal bovine serum (Invitrogen), 100 IU/ml penicillin and 100 μg/ml
streptomycin (Invitrogen) at 37 °C in a 5% CO2 humidiﬁed incubator.
COS-7 cells were transfected with expression plasmids by means of
Lipofectamin 2000 (Invitrogen) according to the manufacturer’s in-
struction.
2.6. Flow cytometry
Surface expression of the β2 integrins was determined by ﬂow
cytometry on a FACScan ﬂow cytometer and analyzed by Cell Quest
software (Becton Dickinson, Mountain View, CA, USA). The expression
of heterodimers was determined from 1 × 104 cells for each group.
Transfected COS-7 cells stained with integrin β2 antibody (IB4),
(Integrin b2 (IB4): sc-65254, Santa Cruz) followed by PE-conjugated
goat anti-mouse IgG: sc-3738. Isotype control was normal mouse IgG2a:
sc-3878.
2.7. Statistical analysis
Every assay was performed independently with duplicate samples
and was repeated three times. Statistical analysis was performed with
the Mann–Whitney U test. The statistical signiﬁcance of the diﬀerence
between the control and other groups was evaluated with a one-way
ANOVA. The criterion for statistical signiﬁcance was taken as
P< 0.05.
3. Results
3.1. Clinical and laboratory ﬁnding
In this study, the most common clinical presentation among the
patients were recurrent bacterial infection, diarrhea and skin ulcers.
The other common clinical presentation were omphalitis, delayed
Fig. 3. Mutations in CD18 found in LAD patients. The novel mutation found in this study is shown. Here, it is clear that the C562Y mutation has occurred in the tail domain or Cysteine-
rich region that is very conserved.
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umblical cord separation (after 19 ± 1 day), periodontis, otitis media,
cellulitis, pneumonia, sepsis, ophtus,cervical lymphadenopathy, osteo-
myelitis. In most patients, skin ulcers were ﬁrst clinical presentation.
The patients were presented with leukocytosis and neutrophilia.
3.2. Mutation analysis
Beside clinical features including infection, omphalitis and delayed
umbilical cord separation, ﬂow cytometery study of patients conﬁrmed
the defect in CD18 expression, indicating that mutations in the ITGB2
gene may confer this eﬀect on its expression.
Genomic DNA taken from each subject was successfully PCR-
ampliﬁed for target exons and ﬂanking sequences. The ampliﬁed targets
were sequenced and sequence analysis was performed for identifying
any possible variant in ITGB2, (Fig. 1). Mutations and variants found in
CD18 are summarized in Table 1. In addition to previously reported
mutations, we found one novel mutation NM_000211.4 (ITGB2):
c.1685G>A, predicting p.Cys562Tyr. In silico prediction of the eﬀect
of these mutations on protein structure and stability is shown in
Table 2.
3.3. Expression of heterodimer of mutant CD18/normal CD11a subunit
Flow cytometric analysis of cloned cDNA encoding normal CD18
and normal CD11a subunit indicated eﬀective expression of CD11a/
CD18 (Fig. 2-A). Our ﬂow cytometery data disclosed that cDNA
containing CD18Asp128Tyr can noticeably reduce LAF-1 heterodimers
on the surface of transfected COS-7 cells, (Fig. 2-B). Co-transfection of
COS-7 cells with mutant CD18Trp252Arg with wild-type CD11a also
revealed that the substitution of tryptophan with arginine at the amino
acid position 252 leads to a defect in surface expression of the CD18/
CD11a heterodimer (Fig. 2-C), P< 0.005). Finally, expression analysis
of COS-7 cells transfected with cDNA carrying CD18Cys562Tyr together
with wild-type CD11a disclosed that the substitution of Cysteine with
Tyrosine dramatically decreases the formation of CD18/CD11a com-
plex, P < 0.005. (Fig. 2-D).
4. Discussion
In the current study, we describe the clinical, laboratory and
molecular characteristics of three patients with LAD-I. Genetic altera-
tions in ITGB2 were investigated by PCR sequencing of genomic DNA
from patients. We introduced two previously reported mutations
p.Asp128Tyr [20] and p.Trp252Arg [15] and the novel mutation
p.Cys562Tyr into synthetic cDNA encoding CD18, transfected COS-7
cells with these constructs together with wild-type CD11a and mea-
sured by ﬂow cytometry their ability to form heterodimers.
The β2 subunit of integrins has several domains, which are shown in
Fig. 3. Asp128 is located in the β1 domain of the integrin beta-2 chain
(Fig. 3). Aspartic acid is a negatively charged amino acid. According to
Pfam database of protein families (Pfam: PF08441), aspartic acid of
codon 128 is one of the most conserved positions in CD18. This region
is believed to have a crucial role in the formation of integrin alpha-beta
heterodimers. According to bioinformatic analysis, substitution of this
conserved amino acid with tyrosine seems to be damaging and to
decrease the stability of protein structure (Table 2). Therefore, the
substitution of aspartic acid with the neutral amino acid tyrosine
suggests a pathogenic role of this mutation in LAD-I. We analyzed the
eﬀect of p.Asp128Tyr missense mutation on membrane heterodimer
formation with the CD11a subunit (Fig. 2-B). We found that this genetic
alteration caused reduction of heterodimer formation of CD18 and
CD11a subunit in COS-7 cells.
The second mutation studied was the substitution of tryptophan
with arginine located in codon 252 (p.Trp252Arg). In silico analysis of
this mutation disclosed that it can be pathogenic by decreasing the
stability of CD18 protein structure (Table 2). Investigation of COS cells
transfected with vector containing mutant cDNA showed that this
alteration exerts a deﬁciency in the complex formation of CD18 and
CD11b molecules on the cell surface (Fig. 2-C). The wild-type trypto-
phan is located in a position that is highly conserved in all other
integrin β2 subunits and critical for the maintenance of the αβ
heterodimer conﬁguration [15]. Thus, the p.Trp252Arg mutation seems
to aﬀect protein structure and consequently CD18 function.
Cysteine-562 is located in a major cysteine-rich region at the C-
terminal side of the extracellular domain of the CD18 protein. This
cysteine-rich region is very conserved in human β-integrin molecules.
This region is believed to be crucial for the formation of the tertiary
structure of the aminoterminal and extracellular region of the CD18
protein, because disulﬁde bonds play an important role in the folding
and stability of proteins. Disulﬁde bonds in proteins are formed
between the thiol groups of cysteine residues by the process of oxidative
folding, so cysteine is an essential amino acid that participates in
disulﬁde bonding [21]. Deletion of a cysteine residue is thought to
change the normal pattern of disulﬁde bonding in this region. In
previous reports, co-transfection of COS cells with CD11 subunits and
CD18 mutant in the cysteine-rich region showed low expression of LFA-
1 and Mo-1 [15]. In the current study, we found a novel mutation in
codon 562, where cysteine is substituted with tyrosine. Co-transfection
of COS cells with cDNA containing CD11a and CD18Cys562Tyr revealed
decreased expression of CD11a/CD18 complex (Fig. 2-D). According to
clinical, molecular, and functional results, CD18Cys562Tyr seems to have
a pathogenic impact by interfering with the formation of CD11/CD18
complexes and protein structure and thereby its function. The in silico
analysis of the novel mutation (Table 2) conﬁrmed our experimental
ﬁndings. Based on these bioinformatics tools, this substitution is
damaging and possibly decreases the stability of protein structure.
We recommend that the CD18 p.Cys562Tyr mutation is included in
the panel of carrier and prenatal diagnosis programs for LAD-I.
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